Oncology

Patients with non–small cell lung cancer (NSCLC) had an objective response rate of about 77%.

SHR-A1811 is a novel HER2-targeting ADC comprised of trastuzumab linked to a topoisomerase I inhibitor payload via a cleavable linker.

Scott Tagawa, MD, professor of medicine and urology at Weill Cornell Medicine, discusses safety and tolerability findings observed to date, renal and hematologic considerations, and the role of pharmacists.

The FDA approves Poherdy, a new biosimilar to Perjeta, enhancing treatment options for HER2+ breast cancer patients with affordability and efficacy.

Ziftomenib gains FDA approval as a targeted treatment for relapsed acute myeloid leukemia with NPM1 mutations, offering new hope for patients.

CAR T-cell therapy revolutionizes cancer treatment but poses significant financial and logistical burdens, impacting patient access and outcomes.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

New research highlights the benefits of combining lutetium PSMA 617 with standard treatments, showing improved outcomes for prostate cancer patients.

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

Leukogene's M2T-CD33 gains FDA orphan drug status, promising a novel immunotherapy approach for acute myeloid leukemia treatment.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.

Although further data will be presented in 2026, lifileucel shows promise as a 1-time treatment for advanced non–small cell lung cancer (NSCLC).

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

A retrospective chart review demonstrates the safety of using monoclonal antibodies that are produced with Chinese hamster ovary cells in patients with an allergy to alpha gal.

Researchers explore HER3-targeted therapy with patritumab deruxtecan to enhance outcomes in early-stage triple-negative breast cancer, reducing chemotherapy side effects.

Research reveals a notable risk of invasive fungal infections in multiple myeloma patients undergoing BCMA-targeted CAR T-cell therapy, highlighting the need for vigilant monitoring.

New strategies target dormant tumor cells in breast cancer, offering hope for preventing recurrence and transforming patient management.

FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.

As cellular and bispecific immunotherapies move into earlier treatment lines, pharmacists are interpreting new guidelines, managing toxicities, and shaping patient care strategies.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

Data from multiple KEYNOTE clinical trials support the sustained survival benefits of pembrolizumab in non–small cell lung cancer (NSCLC).

Recent research reveals rising cancer rates among younger and older adults, linking obesity to increased incidence.

Oncologists increasingly embrace cell and gene therapies, yet barriers like cost and perceptions of risk hinder broader adoption.

A phase 2 trial suggests a stepwise regimen using liposomal irinotecan followed by oxaliplatin may improve progression-free survival over standard treatment.